Oct 5, 2024, 09:20
DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO
ASCO shared a post on X:
“Experts Giuseppe Curigliano & Aditya Bardia discuss the results of the DESTINY-Breast06 trial, which showed significant PFS improvement with T-DXd in pts with HR+, HER2-low metastatic.”
Authors: Giuseppe Curiglian and Aditya Bardia
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 5, 2024, 23:12
Dec 5, 2024, 23:08
Dec 5, 2024, 23:04
Dec 5, 2024, 23:01
Dec 5, 2024, 22:59
Dec 5, 2024, 22:57
Dec 5, 2024, 22:55
Dec 5, 2024, 22:53
Dec 5, 2024, 22:51
Dec 5, 2024, 22:48